Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2007

Open Access 01-12-2007 | Research article

Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes

Authors: Annemarie MM Vlaar, Marinus JPG van Kroonenburgh, Alfons GH Kessels, Wim EJ Weber

Published in: BMC Neurology | Issue 1/2007

Login to get access

Abstract

Background

Parkinson's disease (PD) is the second most common neurodegenerative disorder. One of the most widely used techniques to diagnose PD is a Single Photon Emission Computer Tomography (SPECT) scan to visualise the integrity of the dopaminergic pathways in the brain. Despite this there remains some discussion on the value of SPECT in the differential diagnosis of PD. We did a meta-analysis of all the existing literature on the diagnostic accuracy of both pre- and post-synaptic SPECT imaging in the differential diagnosis of PD.

Methods

Relevant studies were searched in Medline, EMBASE and Cochrane databases with back-searching of their reference lists. We limited our analysis to studies with a clinically relevant methodology: i.e. when they assessed the ability of the SPECT to provide 1. diagnosis of PD in an early phase vs. normalcy; 2 diagnostic differentiation between PD and essential tremor (ET); 3. distinguishing between PD and vascular parkinsonism (VP); 4. delineation of PD from atypical parkinsonian syndromes (APS). Gold standard was, dependent on the study type, clinical examination at initial visit or follow-up, and/or response to dopaminergic agents.

Results

The search gave 185 hits, of which we deemed 32 suitable for our analysis. From these we recalculated the diagnostic odds ratio of SPECT for the clinical questions above. The pooled odds ratio (with 95%CI) for presynaptic SPECT scan's ability to distinguish between early PD and normalcy was 60 (13 – 277). For the ability to differentiate between PD and ET this ratio was 210 (79–562). The ratio for presynaptic SPECT's ability to delineate PD from VP was 105 (32 – 348). The mean odds ratio for the presynaptic SPECT scans to differentiate between PD and the two APS was 2 (1 – 4), and for the postsynaptic SPECT imaging this was 19 (9–36).

Conclusion

SPECT with presynaptic radiotracers is relatively accurate to differentiate patients with PD in an early phase from normalcy, patients with PD from those with ET, and PD from VP.
The accuracy of SPECT with both presynaptic and postsynaptic tracers to differentiate between PD and APS is relatively low.
Appendix
Available only for authorised users
Literature
1.
Elbaz A, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA: Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol. 2002, 55: 25-31. 10.1016/S0895-4356(01)00425-5.CrossRefPubMed
2.
Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992, 55: 181-184.CrossRefPubMedPubMedCentral
3.
Koller WC, Montgomery EB: Issues in the early diagnosis of Parkinson's disease. Neurology. 1997, 49: S10-25.CrossRefPubMed
4.
Hughes AJ, Daniel SE, Blankson S, Lees AJ: A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol. 1993, 50: 140-148.CrossRefPubMed
5.
Hughes AJ, Daniel SE, Lees AJ: Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology. 2001, 57: 1497-1499.CrossRefPubMed
6.
Rajput AH, Rozdilsky B, Rajput A: Accuracy of clinical diagnosis in parkinsonism--a prospective study. Can J Neurol Sci. 1991, 18: 275-278.PubMed
7.
Watanabe H, Saito Y, Terao S, Ando T, Kachi T, Mukai E, Aiba I, Abe Y, Tamakoshi A, Doyu M, Hirayama M, Sobue G: Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain. 2002, 125: 1070-1083. 10.1093/brain/awf117.CrossRefPubMed
8.
Litvan I, MacIntyre A, Goetz CG, Wenning GK, Jellinger K, Verny M, Bartko JJ, Jankovic J, McKee A, Brandel JP, Chaudhuri KR, Lai EC, D'Olhaberriague L, Pearce RK, Agid Y: Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998, 55: 969-978. 10.1001/archneur.55.7.969.CrossRefPubMed
9.
Piccini P, Whone A: Functional brain imaging in the differential diagnosis of Parkinson's disease. Lancet Neurol. 2004, 3: 284-290. 10.1016/S1474-4422(04)00736-7.CrossRefPubMed
10.
Clarke CE: Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease. Lancet Neurol. 2004, 3: 466-474. 10.1016/S1474-4422(04)00823-3.CrossRefPubMed
11.
Dujardin K, Defebvre L, Duhamel A, Lecouffe P, Rogelet P, Steinling M, Destee A: Cognitive and SPECT characteristics predict progression of Parkinson's disease in newly diagnosed patients. J Neurol. 2004, 251: 1383-1392. 10.1007/s00415-004-0549-2.CrossRefPubMed
12.
Ponsen MM, Stoffers D, Booij J, van Eck-Smit BLF, Wolters EC, Berendse HW: Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol. 2004, 56: 173-181. 10.1002/ana.20160.CrossRefPubMed
13.
Storch A, Hofer A, Kruger R, Schulz JB, Winkler J, Gerlach M: New developments in diagnosis and treatment of Parkinson's disease--from basic science to clinical applications. J Neurol. 2004, 251 Suppl 6: VI/33-8.
14.
Walter U, Klein C, Hilker R, Benecke R, Pramstaller PP, Dressler D: Brain parenchyma sonography detects preclinical parkinsonism. Mov Disord. 2004, 19: 1445-1449. 10.1002/mds.20232.CrossRefPubMed
15.
Fernandez HH, Friedman JH, Fischman AJ, Noto RB, Lannon MC: Is altropane SPECT more sensitive to fluoroDOPA PET for detecting early Parkinson's disease?. Med Sci Monit. 2001, 7: 1339-1343.PubMed
16.
Huang WS, Chiang YH, Lin JC, Chou YH, Cheng CY, Liu RS: Crossover study of (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson's disease patients. J Nucl Med. 2003, 44: 999-1005.PubMed
17.
Ishikawa T, Dhawan V, Kazumata K, Chaly T, Mandel F, Neumeyer J, Margouleff C, Babchyck B, Zanzi I, Eidelberg D: Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med. 1996, 37: 1760-1765.PubMed
18.
Schwarz J, Antonini A, Tatsch K, Kirsch CM, Oertel WH, Leenders KL: Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism. Nucl Med Commun. 1994, 15: 806-813. 10.1097/00006231-199410000-00006.CrossRefPubMed
19.
Booij J, Tissingh G, Winogrodzka A, van Royen EA: Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med. 1999, 26: 171-182. 10.1007/s002590050374.CrossRefPubMed
20.
Jankovic J, Rajput AH, McDermott MP, Perl DP: The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol. 2000, 57: 369-372. 10.1001/archneur.57.3.369.CrossRefPubMed
21.
Walker Z, Costa DC, Walker RW, Shaw K, Gacinovic S, Stevens T, Livingston G, Ince P, McKeith IG, Katona CL: Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry. 2002, 73: 134-140. 10.1136/jnnp.73.2.134.CrossRefPubMedPubMedCentral
22.
Deville WL, Bossuyt PM, de Vet HC, Bezemer PD, Bouter LM, Assendelft WJ: Systematic reviews in practice. X. Searching, selecting and the methodological assessment of diagnostic evaluation research. Ned Tijdschr Geneeskd. 2002, 146: 2281-2284.PubMed
23.
Assendelft WJ, van Tulder MW, Scholten RJ, Bouter LM: [The practice of systematic reviews. II. Searching and selection of studies]. Ned Tijdschr Geneeskd. 1999, 143: 656-661.PubMed
24.
Deville WL, Buntinx F, Bouter LM, Montori VM, de Vet HC, van der Windt DA, Bezemer PD: Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol. 2002, 2: 9-10.1186/1471-2288-2-9.CrossRefPubMedPubMedCentral
25.
Whiting PF, Weswood ME, Rutjes AW, Reitsma JB, Bossuyt PN, Kleijnen J: Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol. 2006, 6: 9-10.1186/1471-2288-6-9.CrossRefPubMedPubMedCentral
26.
Egger M, Smith GD, Altman DG: Systematic reviews in health care. BMJ Publishing Group, London. 2005, 271-
27.
28.
Vlaar AMM, Kessels AGH, Nijs de T, Winogrodzka A, Mess WH, Kroonenburgh MJPG, Weber WEJ: Additional value of SPECT imaging in comparance with clinical diagnosis in 248 patients with parkinsonism. Movement Disorders. 2007, 22 (Suppl 16): 233-
29.
Brucke T, Asenbaum S, Pirker W, Djamshidian S, Wenger S, Wober C, Muller C, Podreka I: Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl. 1997, 50: 9-24.CrossRefPubMed
30.
Lu CS, Weng YH, Chen MC, Chen RS, Tzen KY, Wey SP, Ting G, Chang HC, Yen TC: 99mTc-TRODAT-1 imaging of multiple system atrophy. J Nucl Med. 2004, 45: 49-55.PubMed
31.
Popperl G, Radau P, Linke R, Hahn K, Tatsch K: Diagnostic performance of a 3-D automated quantification method of dopamine D2 receptor SPECT studies in the differential diagnosis of parkinsonism. Nucl Med Commun. 2005, 26: 39-43. 10.1097/00006231-200501000-00007.CrossRefPubMed
32.
Swanson RL, Newberg AB, Acton PD, Siderowf A, Wintering N, Alavi A, Mozley PD, Plossl K, Udeshi M, Hurtig H: Differences in [99mTc]TRODAT-1 SPECT binding to dopamine transporters in patients with multiple system atrophy and Parkinson's disease. Eur J Nucl Med Mol Imaging. 2005, 32: 302-307. 10.1007/s00259-004-1667-x.CrossRefPubMed
33.
Asenbaum S, Pirker W, Angelberger P, Bencsits G, Pruckmayer M, Brucke T: [123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm. 1998, 105: 1213-1228. 10.1007/s007020050124.CrossRefPubMed
34.
Schwarz J, Tatsch K, Gasser T, Arnold G, Pogarell O, Kunig G, Oertel WH: 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism. Mov Disord. 1998, 13: 16-19. 10.1002/mds.870130107.CrossRefPubMed
35.
Schwarz J, Tatsch K, Arnold G, Ott M, Trenkwalder C, Kirsch CM, Oertel WH: 123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism. Neurology. 1993, 43: S17-20.PubMed
36.
Booij J, Speelman JD, Horstink MW, Wolters EC: The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med. 2001, 28: 266-272. 10.1007/s002590000460.CrossRefPubMed
37.
Schwarz J, Tatsch K, Gasser T, Arnold G, Oertel WH: [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy. Mov Disord. 1997, 12: 898-902. 10.1002/mds.870120610.CrossRefPubMed
38.
Lokkegaard A, Werdelin LM, Friberg L: Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. Eur J Nucl Med Mol Imaging. 2002, 29: 1623-1629. 10.1007/s00259-002-0938-7.CrossRefPubMed
39.
Stoffers D, Booij J, Bosscher L, Winogrodzka A, Wolters EC, Berendse HW: Early-stage [(123)I]beta-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson's disease. Eur J Nucl Med Mol Imaging. 2005
40.
Haapaniemi TH, Ahonen A, Torniainen P, Sotaniemi KA, Myllyla VV: [123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients. Mov Disord. 2001, 16: 124-130. 10.1002/1531-8257(200101)16:1<124::AID-MDS1007>3.0.CO;2-R.CrossRefPubMed
41.
Huang WS, Lin SZ, Lin JC, Wey SP, Ting G, Liu RS: Evaluation of early-stage Parkinson's disease with 99mTc-TRODAT-1 imaging. J Nucl Med. 2001, 42: 1303-1308.PubMed
42.
Schwarz J, Linke R, Kerner M, Mozley PD, Trenkwalder C, Gasser T, Tatsch K: Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson's disease: implications for a preclinical diagnosis. Arch Neurol. 2000, 57: 205-208. 10.1001/archneur.57.2.205.CrossRefPubMed
43.
Van Laere K, De Ceuninck L, Dom R, Van den Eynden J, Vanbilloen H, Cleynhens J, Dupont P, Bormans G, Verbruggen A, Mortelmans L: Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-1. Eur J Nucl Med Mol Imaging. 2004, 31: 1119-1127. 10.1007/s00259-004-1480-6.CrossRefPubMed
44.
Muller T, Farahati J, Kuhn W, Eising EG, Przuntek H, Reiners C, Coenen HH: [123I]beta-CIT SPECT visualizes dopamine transporter loss in de novo parkinsonian patients. Eur Neurol. 1998, 39: 44-48. 10.1159/000007896.CrossRefPubMed
45.
Lee MS, Kim YD, Im JH, Kim HJ, Rinne JO, Bhatia KP: 123I-IPT brain SPECT study in essential tremor and Parkinson's disease. Neurology. 1999, 52: 1422-1426.CrossRefPubMed
46.
Plotkin M, Amthauer H, Klaffke S, Kuhn A, Ludemann L, Arnold G, Wernecke KD, Kupsch A, Felix R, Venz S: Combined (123)I-FP-CIT and (123)I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm. 2005, 112: 677-692. 10.1007/s00702-004-0208-x.CrossRefPubMed
47.
Eerola J, Tienari PJ, Kaakkola S, Nikkinen P, Launes J: How useful is [123I]beta-CIT SPECT in clinical practice?. J Neurol Neurosurg Psychiatry. 2005, 76: 1211-1216. 10.1136/jnnp.2004.045237.CrossRefPubMedPubMedCentral
48.
Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, Speelman JD, Horstink MH, Sips HJ, Dierckx RA, Versijpt J, Decoo D, Van Der Linden C, Hadley DM, Doder M, Lees AJ, Costa DC, Gacinovic S, Oertel WH, Pogarell O, Hoeffken H, Joseph K, Tatsch K, Schwarz J, Ries V: Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord. 2000, 15: 503-510. 10.1002/1531-8257(200005)15:3<503::AID-MDS1013>3.0.CO;2-V.CrossRefPubMed
49.
Gerschlager W, Bencsits G, Pirker W, Bloem BR, Asenbaum S, Prayer D, Zijlmans JC, Hoffmann M, Brucke T: [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. Mov Disord. 2002, 17: 518-523. 10.1002/mds.10092.CrossRefPubMed
50.
Kim YJ, Ichise M, Ballinger JR, Vines D, Erami SS, Tatschida T, Lang AE: Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord. 2002, 17: 303-312. 10.1002/mds.10042.CrossRefPubMed
51.
Messa C, Volonte MA, Fazio F, Zito F, Carpinelli A, d'Amico A, Rizzo G, Moresco RM, Paulesu E, Franceschi M, Lucignani G: Differential distribution of striatal [123I]beta-CIT in Parkinson's disease and progressive supranuclear palsy, evaluated with single-photon emission tomography. Eur J Nucl Med. 1998, 25: 1270-1276. 10.1007/s002590050295.CrossRefPubMed
52.
Pirker W, Djamshidian S, Asenbaum S, Gerschlager W, Tribl G, Hoffmann M, Brucke T: Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord. 2002, 17: 45-53. 10.1002/mds.1265.CrossRefPubMed
53.
Oyanagi C, Katsumi Y, Hanakawa T, Hayashi T, Thuy DD, Hashikawa K, Nagahama Y, Fukuyama H, Shibasaki H: Comparison of striatal dopamine D2 receptors in Parkinson's disease and progressive supranuclear palsy patients using [123I] iodobenzofuran single-photon emission computed tomography. J Neuroimaging. 2002, 12: 316-324.CrossRefPubMed
54.
Oertel WH, Schwarz J, Tatsch K, Arnold G, Gasser T, Kirsch CM: IBZM-SPECT as predictor for dopamimetic responsiveness of patients with de novo parkinsonian syndrome. Adv Neurol. 1993, 60: 519-524.PubMed
55.
Tatsch K, Schwarz J, Oertel WH, Kirsch CM: SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease. Nucl Med Commun. 1991, 12: 699-707. 10.1097/00006231-199108000-00005.CrossRefPubMed
56.
Buck A, Westera G, Sutter M, Albani C, Kung HF, vonSchulthess GK: Iodine-123-IBF SPECT evaluation of extrapyramidal diseases. J Nucl Med. 1995, 36: 1196-1200.PubMed
57.
Seppi K, Schocke MF, Donnemiller E, Esterhammer R, Kremser C, Scherfler C, Diem A, Jaschke W, Wenning GK, Poewe W: Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease. Mov Disord. 2004, 19: 1438-1445. 10.1002/mds.20229.CrossRefPubMed
58.
Schelosky L, Hierholzer J, Wissel J, Cordes M, Poewe W: Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT. Mov Disord. 1993, 8: 453-458. 10.1002/mds.870080406.CrossRefPubMed
59.
Pirker W, Asenbaum S, Wenger S, Kornhuber J, Angelberger P, Deecke L, Podreka I, Brucke T: Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease. J Nucl Med. 1997, 38: 1711-1717.PubMed
60.
van Royen E, Verhoeff NF, Speelman JD, Wolters EC, Kuiper MA, Janssen AG: Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography. Arch Neurol. 1993, 50: 513-516.CrossRefPubMed
61.
Pirker W, Asenbaum S, Bencsits G, Prayer D, Gerschlager W, Deecke L, Brucke T: [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord. 2000, 15: 1158-1167. 10.1002/1531-8257(200011)15:6<1158::AID-MDS1015>3.0.CO;2-0.CrossRefPubMed
62.
Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM, Charney DS, van Dyck CH, Innis RB: Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med. 1998, 39: 1500-1508.PubMed
63.
Booij J, Tissingh G, Winogrodzka A, Boer GJ, Stoof JC, Wolters EC, van Royen EA: Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur J Nucl Med. 1997, 24: 68-71. 10.1007/BF01728311.CrossRefPubMed
64.
Hierholzer J, Cordes M, Venz S, Schelosky L, Harisch C, Richter W, Keske U, Hosten N, Maurer J, Poewe W, Felix R: Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes. J Nucl Med. 1998, 39: 954-960.PubMed
65.
Pirker W, Holler I, Gerschlager W, Asenbaum S, Zettinig G, Brucke T: Measuring the rate of progression of Parkinson's disease over a 5-year period with beta-CIT SPECT. Mov Disord. 2003, 18: 1266-1272. 10.1002/mds.10531.CrossRefPubMed
66.
Booij J, Bergmans P, Winogrodzka A, Speelman JD, Wolters EC: Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease. Synapse. 2001, 39: 101-108. 10.1002/1098-2396(200102)39:2<101::AID-SYN1>3.0.CO;2-1.CrossRefPubMed
67.
van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM, Innis RB: Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry. 2002, 10: 36-43. 10.1176/appi.ajgp.10.1.36.CrossRefPubMed
68.
Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ: Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003, 54: 93-101. 10.1002/ana.10609.CrossRefPubMed
69.
Fahn S: Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. Arch Neurol. 1999, 56: 529-535. 10.1001/archneur.56.5.529.CrossRefPubMed
70.
Benamer HT, Oertel WH, Patterson J, Hadley DM, Pogarell O, Hoffken H, Gerstner A, Grosset DG: Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations. Mov Disord. 2003, 18: 977-984. 10.1002/mds.10482.CrossRefPubMed
71.
Lorberboym M, Djaldetti R, Melamed E, Sadeh M, Lampl Y: 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. J Nucl Med. 2004, 45: 1688-1693.PubMed
72.
Schwarz J, Kraft E, Vogl T, Arnold G, Tatsch K, Oertel WH: Relative quantification of signal on T2-weighted images in the basal ganglia: limited value in differential diagnosis of patients with parkinsonism. Neuroradiology. 1999, 41: 124-128. 10.1007/s002340050716.CrossRefPubMed
73.
Pizzolato G, Cagnin A, Rossato A, Chierichetti F, Fabbri M, Dam M, Ferlin G, Battistin L: Striatal dopamine D2 receptor alterations and response to L-DOPA in Parkinson's disease. A [123I]IBZM SPET study. Adv Neurol. 1996, 69: 467-473.PubMed
74.
Schwarz J, Tatsch K, Arnold G, Gasser T, Trenkwalder C, Kirsch CM, Oertel WH: 123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism. Neurology. 1992, 42: 556-561.CrossRefPubMed
75.
Hierholzer J, Cordes M, Schelosky L, Sander B, Bock JC, David I, Horowski R, Poewe W: [The differential diagnosis of Parkinson diseases--123I-IBZM-SPECT vs. the apomorphine test]. Rofo. 1993, 159: 86-90.CrossRefPubMed
76.
Knudsen GM, Karlsborg M, Thomsen G, Krabbe K, Regeur L, Nygaard T, Videbaek C, Werdelin L: Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy. Eur J Nucl Med Mol Imaging. 2004, 31: 1631-1638. 10.1007/s00259-004-1578-x.CrossRefPubMed
77.
Prunier C, Tranquart F, Cottier JP, Giraudeau B, Chalon S, Guilloteau D, De Toffol B, Chossat F, Autret A, Besnard JC, Baulieu JL: Quantitative analysis of striatal dopamine D2 receptors with 123 I-iodolisuride SPECT in degenerative extrapyramidal diseases. Nucl Med Commun. 2001, 22: 1207-1214. 10.1097/00006231-200111000-00007.CrossRefPubMed
78.
Schulz JB, Klockgether T, Petersen D, Jauch M, Muller-Schauenburg W, Spieker S, Voigt K, Dichgans J: Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT. J Neurol Neurosurg Psychiatry. 1994, 57: 1047-1056.CrossRefPubMedPubMedCentral
79.
Berding G, Gratz KF, Kolbe H, Meyer GJ, Dengler R, Knoop BO, Hundeshagen H: 123I-IBZM SPECT: reconstruction methodology and results in parkinsonism and dystonia. Nuklearmedizin. 1994, 33: 194-199.PubMed
80.
Bettin S, Kampfer I, Seese A, Schafer A, Reuter M, Lossner J, Dietrich J, Wagner A, Knapp WH: [Striatal uptake of I-123-beta-CIT and I-123-IBZM in patients with extrapyramidal symptoms]. Nuklearmedizin. 1997, 36: 167-172.PubMed
81.
Scherfler C, Seppi K, Donnemiller E, Goebel G, Brenneis C, Virgolini I, Wenning GK, Poewe W: Voxel-wise analysis of [123I] beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. Brain. 2005
82.
Staffen W, Mair A, Unterrainer J, Trinka E, Ladurner G: Measuring the progression of idiopathic Parkinson's disease with [123I] beta-CIT SPECT. J Neural Transm. 2000, 107: 543-552. 10.1007/s007020070077.CrossRefPubMed
83.
Thobois S, Jahanshahi M, Pinto S, Frackowiak R, Limousin-Dowsey P: PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences. Neuroimage. 2004, 23: 1-16. 10.1016/j.neuroimage.2004.04.039.CrossRefPubMed
84.
Parkinson Study Group: A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology. 2000, 55: 1540-1547.CrossRef
Metadata
Title
Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes
Authors
Annemarie MM Vlaar
Marinus JPG van Kroonenburgh
Alfons GH Kessels
Wim EJ Weber
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2007
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/1471-2377-7-27

Other articles of this Issue 1/2007

BMC Neurology 1/2007 Go to the issue

Research article

Clinical outcome following acute ischaemic stroke relates to both activation and autoregulatory inhibition of cytokine production

Research article

Neuroserpin polymorphisms and stroke risk in a biracial population: the stroke prevention in young women study

Research article

Brain type carnosinase in dementia: a pilot study

Study protocol

Protocol of a prospective study on the diagnostic value of transcranial duplex scanning of the substantia nigra in patients with parkinsonian symptoms

Study protocol

Supported treadmill training to establish walking in non-ambulatory patients early after stroke

Research article

Differential expression of the capsaicin receptor TRPV1 and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy